LY 3023414

Drug Profile

LY 3023414

Alternative Names: LY3023414

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; Sarah Cannon Research Institute
  • Developer Eli Lilly; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 29 Oct 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 08 Sep 2017 Interim efficacy and adverse events data from the phase I KEYNOTE238 trial in Non small cell lung cancer (Combination therapy, Late-stage disease) were presented at the 42nd European Society for Medical Oncology Congress
  • 01 Sep 2017 Eli Lilly completes a phase II trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT02443337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top